Advertisement

European Journal of Dermatology

, Volume 28, Issue 3, pp 356–363 | Cite as

Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study

  • Christopher E. M. Griffiths
  • Linda Stein Gold
  • Frédéric Cambazard
  • Robert E. Kalb
  • David Lowson
  • Anders Møller
  • Carle Paul
Therapy
  • 9 Downloads

Abstract

Background

Health-related quality of life (HRQoL) measures provide patient-centred evaluations of response to treatment. In the 12-week, Phase III PSO-ABLE study, fixed-combination calcipotriol 50 μg/g as hydrate (Cal) plus betamethasone 0.5 mg/g as dipropionate (BD) aerosol foam was significantly more effective for the treatment of psoriasis than Cal/BD gel.

Objective

To compare HRQoL in mild-severe psoriasis vulgaris patients (involving 2-30% body surface area) over 12 weeks of treatment with Cal/BD foam or gel.

Methods

HRQoL was assessed using: Dermatology Life Quality Index (DLQI), EuroQoL-5D-5L-PSO (EQ-5D), and Psoriasis QoL (PQoL-12) questionnaires (baseline, Weeks 4, 8 and 12); DLQI score of 0/1 (range: 0-30) and weighted EQ-5D utility index score of 1 (range: 0-1) indicates there is no impact on a patient’s QoL and perfect health, respectively. Itch, itch-related sleep loss, and work impairment were also assessed.

Results

In total, 463 patients were randomized to the study (Cal/BD foam, n = 185; Cal/BD gel, n = 188; foam vehicle, n = 47; gel vehicle, n = 43). Significantly more Cal/BD foam patients achieved DLQI scores of 0/1 at Weeks 4 (45.7% vs 32.4%; p = 0.013) and 12 (60.5% vs 44.1%; p = 0.003) than Cal/BD gel patients. Cal/BD foam significantly improved EQ-5D utility index (0.09 vs 0.03; p<0.001) and PQoL-12 scores (-2.23 vs -2.07; p = 0.029) from baseline to Week 4 versus Cal/BD gel. Itch, itch-related sleep loss, and work impairment improved more with Cal/BD foam than gel.

Conclusion

Cal/BD foam demonstrated greater HRQoL improvement in patients with psoriasis than Cal/BD gel over 12 weeks of treatment.

Key words

aerosol foam calcipotriol betamethasone dipropionate psoriasis vulgaris quality of life 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hrehorow E, Salomon J, Matusiak L, Reich A, Szepietowski JC. Patients with psoriasis feel stigmatized. Acta Derm Venereol 2012; 92: 67–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Langley RG, Krueger GG, Griffiths CE. Psoriasis:epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(Suppl 2):ii18–23.Google Scholar
  3. 3.
    Heller MM, Wong JW, Nguyen TV, et al. Quality–of–life instruments:evaluation of the impact of psoriasis on patients. Dermatol Clin 2012; 30: 281–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five–level version of EQ–5D (EQ–5D–5L). Qual Life Res 2011; 20: 1727–36.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4: 35.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother 2010; 11: 1999–2009.CrossRefPubMedGoogle Scholar
  7. 7.
    Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 2011;25(Suppl 4):9–14.Google Scholar
  8. 8.
    Hollesen Basse L, Olesen M, Lacour JP, Queille–Roussel C. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol 2014;134:S33, abst 192.Google Scholar
  9. 9.
    Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris–a randomized Phase II study. J Dermatolog Treat 2016; 27: 120–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris:a randomized, double–blind, multicenter, three–arm, Phase II study. J Clin Aesthet Dermatol 2016; 9: 34–41.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris–a randomized Phase III study (PSO–FAST). J Drugs Dermatol 2015; 14: 1468–77.PubMedGoogle Scholar
  12. 12.
    Queille–Roussel C, Olesen M, Villumsen J, Lacour JP. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig 2015; 35: 239–45.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg 2015; 20: 44–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Paul C, Stein Gold L, Cambazard F, et al. More rapid improvement in quality of life with fixed combination calcipotriene plus betamethasone dipropionate aerosol foam versus topical suspension (PSO–ABLE study in patients with psoriasis vulgaris). J Am Acad Dermatol 2016:P3712.Google Scholar
  15. 15.
    Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy versus gel in patients with psoriasis vulgaris:randomized, controlled PSO–ABLE study. J Eur Acad Dermatol Venereol 2017; 31: 119–26.CrossRefPubMedGoogle Scholar
  16. 16.
    Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients:results of a Phase II study. Health Qual Life Outcomes 2006; 4: 71.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Edson–Heredia E, Barrows S, Masaquel C, Nikai E, Mallbris L, Puig L. The value of achieving complete or near complete resolution of psoriasis. Value Health 2015;18:A427.CrossRefPubMedGoogle Scholar
  18. 18.
    Leonardi C, Bagel J, Yamauchi P, et al. The aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate improves the health–related quality of life in patients with psoriasis vulgaris:results from the randomized PSO–FAST study. J Drugs Dermatol 2016; 15: 981–7.PubMedGoogle Scholar
  19. 19.
    Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life:results of a 1998 National Psoriasis Foundation patient–membership survey. Arch Dermatol 2001; 137: 280–4.PubMedGoogle Scholar
  20. 20.
    Møller AH, Erntoft S, Vinding GR, Jemec GB. A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ–5D–derived utility values. Patient Relat Outcome Meas 2015; 6: 167–77.PubMedPubMedCentralGoogle Scholar
  21. 21.
    van de Kerkhof PC. The impact of a two–compound product containing calcipotriol and betamethasone dipropionate (Daivobet®/Dovobet®) on the quality of life in patients with psoriasis vulgaris:a randomized controlled trial. Br J Dermatol 2004; 151: 663–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis:results from physician interviews and patient focus groups. Health Qual Life Outcomes 2009; 7: 62.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • Christopher E. M. Griffiths
    • 1
  • Linda Stein Gold
    • 2
  • Frédéric Cambazard
    • 3
  • Robert E. Kalb
    • 4
  • David Lowson
    • 5
  • Anders Møller
    • 5
  • Carle Paul
    • 6
  1. 1.Dermatology Centre, Salford Royal HospitalUniversity of ManchesterManchesterUK
  2. 2.Henry Ford Health SystemDetroitUSA
  3. 3.Université Jean MonnetSaint-EtienneFrance
  4. 4.State University of New YorkBuffaloUSA
  5. 5.LEO Pharma A/SBallerupDenmark
  6. 6.Paul Sabatier University and Larrey HospitalToulouseFrance

Personalised recommendations